Biocytogen/Eucure Biopharma Announce the Completio...

BEIJING, December 8, 2021 – Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase II clinical trial of YH003 (anti-CD40 monoclonal antibody, mAb) (No. YH003004) in Australia...

Biocytogen/Eucure Biopharma Announce the Completio...

BEIJING, December 7, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen,announced the completion of first patient dosing for phase I clinical trial of YH004 (anti-4-1BB monoclonal antibody, mAb) (No. YH004002) in Australia...

Biocytogen/Eucure Biopharma's YH001 (Anti-CTLA-4 M...

BEIJING, November 9, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogendedicated to developing proprietary antibody drugs,announced that the China National Medical Products Administration (NMPA) has approved YH001 for phase II Multi-R...

Biocytogen/Eucure Biopharma's YH003 (Anti-CD40 Mon...

BEIJING, November 2, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogendedicated to developing proprietary antibody drugs,announced that the China National Medical Products Administration (NMPA) has approved YH003 for phase II Multi...

Eucure Biopharma, a Subsidiary of Biocytogen, and...

YH001 is a potential best-in-class CTLA-4 antibody with enhanced ADCC and CDC effector functions YH001 is currently being dosed in multiple Phase 1 oncology trials sponsored by Eucure Biopharma in Australia and China TRACON intends to...

Eucure Biopharma to Present Clinical Data Presenta...

BEIJING, September 25-29, 2021 — The 24th National Conference on clinical oncology and the 2021 CSCO annual conference will be held online and offline in the form of seminar and MDT discussion. The theme of this conference is "focus on innovative res...